Skip to content

Early High-Dose Continuous Veno-Venous Hemofiltration Alleviates the Alterations of CD4+ T Lymphocyte Subsets in Patients with Sepsis: A Single-Center Prospective Study

Early High-Dose Continuous Veno-Venous Hemofiltration Alleviates the Alterations of CD4+ T Lymphocyte Subsets in Patients with Sepsis: A Single-Center Prospective Study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100051630
Enrollment
Unknown
Registered
2021-09-28
Start date
2016-06-10
Completion date
Unknown
Last updated
2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Non-CRRT Group:The conventional therapy

Sponsors

The First Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients with sepsis or septic shock were included in the present study if they met the requirement of the third international consensus definitions for sepsis and septic shock (Sepsis-3), accompanied by sepsis-induced acute kidney injury (diagnosed according to the KDIGO clinical practice guidelines) with increase in serum creatinine of more than 300 µmol/L, oliguria (<100 mL/6 h) unresponsive to fluid resuscitation, severe acidemia of less than pH of 7.2, hyperkalemia of more than 6.5 mmol/L, or clinically significant organ edema (e.g., pulmonary edema).

Exclusion criteria

Exclusion criteria: Patients were excluded from the present study based on the following criteria: patients < 18 years old; patients with immunodeficiency virus infection, neutropenia (defined as an absolute neutrophil count of < 1,000 neutrophils/µL), acute bleeding, malignant tumor, pregnancy, or chronic kidney disease; patients who used corticosteroids or nephrotoxic drugs; patients who received any kind of renal replacement therapy prior to admission to the ICU; patients who refused to take part in the present study.

Design outcomes

Primary

MeasureTime frame
T Helper 1 Cells;T Helper 2 Cells;T Helper 17 Cells;T Regulatory cell;

Countries

China

Contacts

Public ContactPing Gong

The First Affiliated Hospital of Dalian Medical University

gongp828@sina.com+86 18098876776

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026